Fig. 3From: Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA reviewStudy 301 high-dose group diverged from an otherwise consistent association between Aβ reduction and slowing of clinical decline. Associations between changes in Aβ and changes in CDR-SB by randomized treatment groups in Studies 103, 301, and 302Back to article page